- Home
- NCDL vs BEATW Comparison
NCDL vs BEATW Comparison
Compare NCDL & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- BEATW
- Stock Information
- Founded
- NCDL 2019
- BEATW 2015
- Country
- NCDL United States
- BEATW United States
- Employees
- NCDL N/A
- BEATW 20
- Industry
- NCDL
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- NCDL
- BEATW Technology
- Exchange
- NCDL NYSE
- BEATW Nasdaq
- Market Cap
- NCDL N/A
- BEATW N/A
- IPO Year
- NCDL N/A
- BEATW N/A
- Fundamental
- Price
- NCDL $16.98
- BEATW $0.51
- Analyst Decision
- NCDL Buy
- BEATW
- Analyst Count
- NCDL 2
- BEATW 0
- Target Price
- NCDL $17.75
- BEATW N/A
- AVG Volume (30 Days)
- NCDL 248.5K
- BEATW 4.7K
- Earning Date
- NCDL 05-08-2025
- BEATW 03-14-2025
- Dividend Yield
- NCDL 12.43%
- BEATW N/A
- EPS Growth
- NCDL N/A
- BEATW N/A
- EPS
- NCDL N/A
- BEATW N/A
- Revenue
- NCDL N/A
- BEATW N/A
- Revenue This Year
- NCDL N/A
- BEATW N/A
- Revenue Next Year
- NCDL N/A
- BEATW N/A
- P/E Ratio
- NCDL N/A
- BEATW N/A
- Revenue Growth
- NCDL N/A
- BEATW N/A
- 52 Week Low
- NCDL $16.20
- BEATW $0.50
- 52 Week High
- NCDL $18.10
- BEATW $0.62
- Technical
- Relative Strength Index (RSI)
- NCDL 36.60
- BEATW N/A
- Support Level
- NCDL $17.14
- BEATW N/A
- Resistance Level
- NCDL $17.59
- BEATW N/A
- Average True Range (ATR)
- NCDL 0.19
- BEATW 0.00
- MACD
- NCDL -0.02
- BEATW 0.00
- Stochastic Oscillator
- NCDL 13.25
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.